Wolfgang Lamm

Wolfgang Lamm

Auto-generated profile, based on publicly available information

Wolfgang Lamm

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MAMarlies Antlanger
Marlies Antlanger
TDTobias Dust
Tobias Dust
TRThomas Reiter
Thomas Reiter
ABAlexandra Böhm
Alexandra Böhm
WLWolfgang W. Lamm
Wolfgang W. Lamm
MKMaria Theresa Krauth
Maria Theresa Krauth
Renal impairment (RI) is a negative prognostic factor in Multiple Myeloma (MM) and affected patients are often excluded from autologous stem cell transplantation (ASCT). However, it remains unclear whether historically inferior outcome data still hold true. From a total of 475 eligible MM patients who had undergone ASCT between 1998 and 2016, 374 were included in this multi-centric retrospective cohort study. Renal function was determined both at the time of MM diagnosis and ASCT by estimated glomerular filtration rate (eGFR according to the MDRD formula, RI defined as eGFR < 60 ml/min/1.73m2). Patients were categorized into 3 groups: A) no RI diagnosis and ASCT, B) RI at diagnosis with normalization before ASCT and C) RI both at the time of diagnosis and ASCT. Log-rank testing was used for overall and progression-free survival (OS, PFS) analysis. While severe RI at MM diagnosis confers a risk of shorter OS, MM progression after ASCT is not affected by any stage of renal failure. It can be concluded that ASCT can be safely carried out in MM patients with mild to moderate RI and should be pro-actively considered in those with severe RI. When comparing all groups, no difference in OS and PFS was found (p = 0.319 and p = 0.904). After further stratification according to the degree of RI at the time of diagnosis, an OS disadvantage was detected for patients with an eGFR < 45 ml/min/m2. PFS was not affected by any RI stage.

18 December 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WLWolfgang Lamm
Wolfgang Lamm
CNCamilla Natter
Camilla Natter
SSSophie Schur
Sophie Schur
Wolfgang J. Köstler, MD, PhDWolfgang J. Köstler, MD, PhD
Wolfgang J. Köstler, MD, PhD
ARAlexander Reinthaller
Alexander Reinthaller
Stephan PolterauerStephan Polterauer
Stephan Polterauer
Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups.

7 September 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
UVUrsula M Vogl
Ursula M Vogl
MBMarija Bojic
Marija Bojic
WLWolfgang Lamm
Wolfgang Lamm
JFJosa M Frischer
Josa M Frischer
OPOskar Pichelmayer
Oskar Pichelmayer
Manuela SchmidingerManuela Schmidinger
Manuela Schmidinger
In the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a significantly shorter survival than patients without. Targeted agents (TA) have improved the outcome of patients with metastatic renal cell carcinoma (mRCC) however, their impact on patients with BM is less clear. The aim of this analysis was to compare the outcome of patients with and without BM in the era of targeted agents.

4 February 2021 in ASAIO Journal
Verified
Journal Article
Closed access
BNBernhard Nagler
Bernhard Nagler
Alexander HermannAlexander Hermann
Alexander Hermann
OROliver Robak
Oliver Robak
PSPeter Schellongowski
Peter Schellongowski
NBNina Buchtele
Nina Buchtele
WLWolfgang Lamm
Wolfgang Lamm
Extracorporeal membrane oxygenation (ECMO) has established as a cornerstone therapy in severe acute respiratory distress syndrome and refractory hemodynamic failure. As circuit integrity is crucial for adequate organ support, component failure may necessitate a system exchange. In this retrospective study, incidence and etiology of system exchanges during applications of venovenous, venoarterial ECMO, and extracorporeal CO2 removal were examined. Sixty-three (44.4%) of 142 patients were affected by one or more exchanges, totaling 105 replaced circuits. The predominant exchange reason was clotting (n = 20), followed by hemolysis (n = 19), systemic coagulation disorders (n = 13), reconfiguration (n = 13), impaired gas exchange (n = 10), mechanical complications (n = 8), bleeding (n = 6), failed weaning (n = 5), prophylactic exchange (n = 3), and undocumented/other (n = 8). Nineteen (18.1%) events were classified as acute and 70 (66.7%) events as elective exchanges. Patients with circuit exchanges more frequently underwent renal replacement therapy at ECMO initiation (49.2% vs. 29.1%; p = 0.023), had a longer ECMO treatment duration (18 vs. 7.5 days, p < 0.001), and lower hospital survival (29.5% vs. 57.1%; p = 0.002). Considering the high occurrence of coagulation complications, further optimization of coagulation management is deemed necessary.

28 February 2019 in The International Journal of Artificial Organs
Verified
Journal Article
Open access
PDF file
WLWolfgang Lamm
Wolfgang Lamm
BNBernhard Nagler
Bernhard Nagler
Alexander HermannAlexander Hermann
Alexander Hermann
OROliver Robak
Oliver Robak
PSPeter Schellongowski
Peter Schellongowski
TSThomas Staudinger
Thomas Staudinger
Patients on extracorporeal membrane oxygenation are frequently in need for sedation. Use of propofol has been associated with impaired oxygenator function due to adsorption to the membrane as well as lipid load. The aim of our retrospective analysis was to compare two different sedation regimens containing either propofol or midazolam with respect to oxygenator running time. Midazolam was used in 73 patients whereas propofol was used in 49 patients, respectively. In the propofol group, veno-arterial–extracorporeal membrane oxygenation was used predominantly (84%), while veno-venous–extracorporeal membrane oxygenation was used more often in the midazolam group (64%). Oxygenator running time until first exchange was 7 days in both groups (p = 0.759). No statistically significant differences could be observed between the subgroup of patients receiving lipid-free (n = 24) and lipid-containing (n = 31) parenteral nutrition, respectively. Laboratory parameters like triglycerides, free hemoglobin, fibrinogen, platelets, and activated partial thromboplastin time were not significantly different between both sedation regimens (p = 0.462, p = 0.489, p = 0.960, p = 0.134, and p = 0.843) and were not associated with oxygenator running time. The use of propofol as sedative seems suitable in patients undergoing extracorporeal membrane oxygenation therapy.

24 January 2019 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
WLWolfgang Lamm
Wolfgang Lamm
WDWerner Dolak
Werner Dolak
BKBarbara Kiesewetter
Barbara Kiesewetter
ISIngrid Simonitsch-Klupp
Ingrid Simonitsch-Klupp
HPHannah Puhr
Hannah Puhr
MRMarkus Raderer
Markus Raderer
Background: The frequency of endoscopically apparent gastrointestinal tract (GI) involvement in patients with mantle cell lymphoma (MCL) at diagnosis is thought to be in the range of 30%. While reports on GI involvement in MCL patients exist, most series lack a strict GI assessment due to the often asymptomatic nature of GI involvement. Owing to the standardized staging routine at our institution including GI assessment at diagnosis, we have analyzed the rate and prognostic impact of GI involvement in MCL. Methods: In this retrospective single-center evaluation, we have investigated GI involvement in 85 consecutive patients with MCL. All data were collected from clinical records. Results: MCL with and without endoscopically detectable GI involvement was reported in 29 (34%) patients and 56 patients (66%), respectively. The colon was involved in 21 (72%) and the stomach in 8 (28%). Eight of 29 patients (28%) had symptomatic GI involvement, and the primary diagnosis had been established in the GI tract in 3/29 (10%) of our patients. No statistical differences could be observed between both groups in terms of gender (p = 0.474), Eastern Cooperative Oncology Group (0.428), and MCL international prognostic index (0.543). Overall survival was longer in patients with GI involvement (116.0 vs. 74 months), but not statistically significant (p = 0.825). Conclusions: In our single center cohort, we did not find a clinical impact of GI involvement on the clinical course of MCL and no GI complications occurred during chemotherapy in these patients. As most patients were also asymptomatic, these data argue against a routine GI assessment in patients diagnosed with MCL.